| |
Anti-TNF treatment(n = 23)
|
Conventional treatment(n = 32)
|
p value
|
|---|
|
BASFI
|
3.7 (1.5–7.7)
|
3.8 (0.1–8.8)
|
0.4
|
|
BASDAI
|
4 (1.3–8.1)
|
5.5 (1–9)
|
0.08
|
|
BASRI-hip
|
0 (0–4)
|
0 (0–2.5)
|
0.1
|
|
BASRI-spine
|
7.5 (2–12)
|
5.5 (2–12)
|
0.09
|
|
BASMI
|
4 (1–9)
|
2 (1–9)
|
0.003
|
|
BMD-Lumbar spine (g/cm2)
|
1 (0.7–1.6)
|
0.9 (0.8–1.4)
|
0.3
|
|
BMD-Femoral neck (g/cm2)
|
0.8 (0.6–1)
|
0.8 (0.5–1.1)
|
0.5
|
|
IL-6 (pg/mL)
|
13 (5–545)
|
20 (6–300)
|
0.9
|
|
IFNγ (pg/ml)
|
0.002 (0.002–0.03)
|
0.002 (0.002–1.96)
|
0.6
|
|
BAP (U/L)
|
33 (17–107)
|
28 (13–47)
|
0.04
|
|
Vitamin D (nM)
|
84 (12–266)
|
92 (4–244)
|
0.9
|
|
NTX (nM, bone collagen
equivalent)
|
78 (52–188)
|
83 (64–114)
|
0.4
|
|
TRAP 5 (U/L)
|
4 (2.3–5.8)
|
3.7 (2.3–6.6)
|
0.3
|
|
hPTH (pg/mL)
|
46 (44–130)
|
46 (44–170)
|
0.8
|
|
sRANKL (pmol/L)
|
284 (103–1598)
|
285 (101–956)
|
0.5
|
|
OPG (pg/mL)
|
274 (52–1080)
|
384 (84–1118)
|
0.04
|
|
sRANKL/OPG
|
1.28 (0.2–22.6)
|
0.73 (0.14–4.5)
|
0.03
|
|
Sclerostin (pmol/L)
|
75 (48–95)
|
68 (49–126)
|
0.6
|
|
sFRP1 (ng/mL)
|
0.1 (0.1–17)
|
0.2 (0.1–0.4)
|
0.1
|
|
DKK1 (pg/mL)
|
108 (39–771)
|
87 (17–370)
|
0.03
|
- Data are presented as the median with minimum and maximum values. BASFI= Bath ankylosing apondylitis functional index, BASDAI= Bath ankylosing spondylitis disease activity index, BASMI= Bath ankylosing spondylitis metrology index, BASRI= Bath Ankylosing spondylitis radiologic index, IL-6= interleukin 6, IFNγ= interferon-gamma, BAP= bone-specific alkaline phosphatase, NTX= cross-linked N-telopeptide of type I collagen, TRAP 5= serum band 5 tartrate-resistant acid phosphatase, hPTH= human parathyroid hormone, sRANKL= soluble receptor activator of nuclear factor kappa-B ligand, OPG= osteoprotegerin, sFRP1= secreted frizzled-related protein 1, DKK1= Dickkopf-related protein 1.
